Design, Synthesis, and Biological Evaluation of New 1,8-Naphthyridin-4(1H)-on-3-carboxamide and Quinolin-4(1H)-on-3-carboxamide Derivatives as CB2Selective Agonists
Citations Over TimeTop 10% of 2006 papers
Abstract
On the basis of docking studies carried out using the recently published cannabinoid receptor models,35 new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives were designed, synthesized, and tested for their affinities toward the cannabinoid CB1 and CB2 receptors. Compound 10, which presented p-fluorobenzyl and carboxycycloheptylamide substituents bound in the 1 and 3 positions of the 1,8-naphthyiridine-4-one nucleus, showed a high CB2 affinity with a Ki of 1.0 nM. The substitution of the naphthyridine-4-one nucleus with the quinoline-4-one system determined a general increase in CB2 affinity. In particular, the N-cyclohexyl-7-chloro-1-(2-morpholin-4-ylethyl)quinolin-4(1H)-on-3-carboxamide (40) possessed a remarkable affinity, with Ki of 3.3 nM, which was also accompanied by a high selectivity for the CB2 receptor (Ki(CB1)/Ki(CB2) ratio greater than 303). Moreover, the [35S]GTPgamma binding assay and functional studies on human basophils indicated that the 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives behaved as CB1 and CB2 receptor agonists.
Related Papers
- → Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor(2000)541 cited
- → Targeting cannabinoid agonists for inflammatory and neuropathic pain(2007)101 cited
- → Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors(2004)99 cited
- → Cannabinoid CB1 and CB2 Receptor Ligand Specificity and the Development of CB2-Selective Agonists(2008)88 cited
- → Identification and biochemical analyses of selective CB2 agonists(2019)10 cited